AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-12 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Massachusetts stating that crime laboratory reports may not be used against criminal defendants at trial unless the analysts responsible for creating them give testimony and subject themselves to cross-examination. The Supreme Court cited the National Academies of Sciences report Strengthening Forensic Science in the United States in their decision. Writing for the majority, Justice Antonin Scalia referred to the National Research Council report in his assertion that "Forensic evidence is not uniquely immune from the risk of manipulation." In the US, another area of forensic science that has come under question in recent years is the lack of laws requiring the accreditation of forensic labs. Some states require accreditation, but some states do not. Because of this, many labs have been caught performing very poor work resulting in false convictions or acquittals. For example, it was discovered after an audit of the Houston Police Department in 2002 that the lab had fabricated evidence which led George Rodriguez being convicted of raping a fourteen-year-old girl. The former director of the lab, when asked, said that the total number of cases that could have been contaminated by improper work could be in the range of 5,000 to 10,000. The Innocence Project database of DNA exonerations shows that many wrongful convictions contained forensic science errors. According to the Innocence project and the US Department of Justice, forensic science has contributed to about 39 percent to 46 percent of wrongful convictions.
==== Art and design of Dishonored ==== Antonov's team was also inspired by older stealth action games developed by Ion Storm and Looking Glass Studios; Robert Purchese wrote for Eurogamer that this likely included Thief: The Dark Project (1998) and Deus Ex (2000). The game's "stylised" character designs were inspired by the "flamboyant" illustrations made for older adventure novels, especially ones about pirates such as Captain Blood (1922). In some cases, rather than using industry artists, Dishonored's developers hired industrial engineers, industrial designers, and other professionals in non-industry fields—including illustrators from Russia—to design the game's assets, as they felt this would make Dunwall's exotic, industrial scenery feel more authentic. For example, Antonov and Sébastien Mitton tracked down a specific textile carpet designer in Russia to have them make key art for the game. Most of the character design was done by professional anatomists. Antonov's main goal in designing Dunwall was "to reduce the scope and increase the density of experience" in exploring game worlds. Inside the city's "claustrophobic" areas, players can navigate small spaces like the underside of a table, and are able to reach and enter any location they can see while playing. Controlling Corvo Attano, an assassin given magical abilities, the player is aided in exploring small spaces by possessing any rats they see in the world, and can use the rat's burrows as shortcuts between locations.
==== Provenance of human remains ==== The geographic variation in DHR in human drinking water is recorded in hair. Studies have shown a very strong relation between an individual's hair and drinking water DHRs. Since tap water DHR depends strongly on geography, a person's hair DHR can be used to determine regions where they most likely lived during hair growth. This idea has been used in criminal investigations to try to constrain the movements of a person prior to their death, in much the same way DHRs have been used to track animal migration. By analyzing sections of hair of varying ages, one can determine in what D/H regions a person was living at a specific time before their death.
=== Equilibrative nucleoside transporters (ENTs) === The nucleoside transporters, or equilibrative nucleoside transporters, are uniporters that transport nucleosides, nucleobases, and therapeutic drugs across the cell membrane. Nucleosides serve as building blocks for nucleic acid synthesis and are key components for energy metabolism in creating ATP/ GTP. They also act as ligands for purinergic receptors such as adenosine and inosine. ENTs allow the transport of nucleosides down their concentration gradient. They also have the ability to deliver nucleoside analogs to intracellular targets for the treatment of tumors and viral infections. ENTs are part of the Major Facilitator Superfamily (MFS) and are suggested to transport nucleosides using a clamp-and-switch model. In this model, the substrate first binds to the transporter, which leads to a conformational change that forms an occluded state (clamp). Then, the transporter switches to face the other side of the membrane and releases the bound substrate (switching). ENTs have been found in protozoa and mammals. In humans, they have been discovered as ENT3 (hENT1-3) and ENT4 (hENT4) transporters. ENTs are expressed across all tissue types, but certain ENT proteins have been found to be more abundant in specific tissues. hENT1 is found mostly in the adrenal glands, ovary, stomach and small intestines. hENT2 is expressed mostly in neurological tissues and small parts of the skin, placenta, urinary bladder, heart muscle and gallbladder.
Sources: en.wikipedia.org
Recently, an efficient stepwise solid-phase synthesis of RANTES (24-91) was published. RANTES is a major HIV-suppressive factor produced by CD8+ T Cells. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) induces a NH2-terminal truncation from RANTES (1-91) to RANTES(24-91), which inhibits the infection of monocytes by an M-tropic HIV-1 strain The 68 amino acid of RANTES(24-91) has a high propensity to aggregate. The method combines the advantages of the PEG-based ChemMatrix resin and pseudoproline dipeptides. Direct coupling to pseudoproline monomer. Senko and his colleagues were the first to confirm the effectiveness of pseudoproline derivatives of individual, single residues in polypeptide synthesis. According to literature, the conversion of Ser(ΨPro) was excellent, however the Thr(ΨPro) varied in a wide range. The acylation of Pseudoproline monomer depended also on the chemical nature of the acylating residue. Manne and his colleagues successfully synthesized a human Growth Hormone (hGH)-derived polypeptide that was previously challenging to access, using Ser(ΨPro), while JR10 utilized Thr(ΨPro). Building upon Senko et al.'s work, Szaniszló and co-workers have recently improved the acylating efficiency of Thr(ΨPro) and incorporated it into their continuous flow peptide synthesizer.
He found chloramines to be the best, for being stable, non-toxic, and not very irritating, yet powerful bactericides, presumably due to their release of hypochlorous acid. However, the difficulty of procuring them led him to choose "hypochlorite of soda" as a practical alternative. Between the two World Wars, the preparation was often called "Carrel–Dakin solution," even though Dakin did the bulk of the research work that led to its formulation. The name of Carrel was dropped after World War II, presumably due to his active involvement in eugenics movements and the advocacy of elimination of "inferior" humans. Since penicillin became established as an antibiotic in 1943, use of Dakin's solution and other topical antiseptics for wound treatment has declined, and their use is frowned upon in modern medical care. However, the solution continues to be used (as of 2023) due to its broad activity against aerobic and anaerobic organisms, including fungi and antibiotic-resistant organisms, its very low cost, and its wide availability. In emergency situations, it can be produced on the field from liquid bleach and sodium bicarbonate.
==== 2020 kimchi ISO standard dispute with China ==== In November 2020, the International Organization for Standardization (ISO) posted ISO 24220:2020, new regulations for the making of pao cai. The same month, BBC News reported that Chinese news organization Global Times claimed the new ISO standard was "an international standard for the kimchi industry led by China" despite the standard clearly stating "this document does not apply to kimchi". This sparked strong anger from South Korean media and people, as well as the responses from some Chinese people who argued China held the right to claim kimchi as their own. However clarifications from both countries, later revealed that the controversy was triggered over a misunderstanding of a translation of the Chinese word pao cai. After the controversy emerged, Global Times explained it was simply a "misunderstanding in translation", where they had meant to refer to Chinese pao cai, and their Chinese language article had used the term pao cai, but their English language version had "erroneously" translated it as "kimchi", and that the dispute arose from being innocently "lost in translation".
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.